• Female patient is at least 18 years of age,

• Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements.

• Patient with histologically proven confirmed recurrent or persistent clear cell carcinoma of the ovary, endometrium, cervix, vagina, and vulva

‣ Local review by gynecologic pathologist required

⁃ ≥50% clear cell histology in case of mixed carcinoma

⁃ WT-1 neg (Only in case of ovarian cancer) Note: In the case of including non-ovarian clear cell carcinoma with more than 20 cases, the decision is made through discussion with the SPONSOR.

• Patient with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

• Disease progression within 12 months of completing platinum-based chemotherapy

• 1-5 prior lines of therapies

• Patient with measurable disease according RECIST 1.1 criteria

• Availability of Tumor tissue for translational research . - A formalin-fixed paraffin-embedded (FFPE) tumor block(preferred) or at least 20 slides (unstained, freshly cut, serial sections) must be submitted.

• Patients who consent to fresh tumor biopsies

‣ Confirmed with at least one lesion with location accessible to safely biopsy per the clinical judgement of the investigator

⁃ Note: If mandatory biopsies cannot be performed as per investigator's clinical judgement, discussion and agreement between investigator and Sponsor are required.

⁃ Patient has adequate organ function, defined as follows:

• Absolute neutrophil count ≥ 1,500 cells/μL

∙ Platelets ≥ 100,000 cells/μL

∙ Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L

∙ Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault equation for patients with creatinine levels \> 1.5× institutional ULN

∙ Total bilirubin ≤ 1.5× ULN (≤ 2.0 x ULN in patients with known Gilbert's syndrome) or direct bilirubin ≤ 1× ULN

∙ Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver metastases are present, in which case they must be ≤ 5× ULN

∙ International normalized ratio or prothrombin time (PT) ≤1.5× ULN and activated partial thromboplastin time ≤1.5× ULN.Participants taking anticoagulants may be included on a stable dose with a therapeutic INR \<3.5. .

⁃ Patient must have a negative serum pregnancy test within 72 hours of the first dose of study medication, unless they are of non-childbearing potential. If a negative result cannot be confirmed by a urine test, a serum pregnancy test is required. Non-childbearing potential is defined as follows:

• Patient is ≥ 45 years of age and has not had menses for \> 1 year.

∙ A follicle-stimulating hormone value in the postmenopausal range upon screening evaluation if amenorrhoeic for \< 2 years without a hysterectomy and oophorectomy.

∙ Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation:

‣ Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, MRI, or CT scan.

⁃ Tubal ligation must be confirmed with medical records of the actual procedure.

⁃ Information must be captured appropriately within the site's source documents.

⁃ Patient of childbearing potential must agree to use a highly effective method of contraception with their partners starting from time of consent through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient (Information must be captured appropriately within the site's source documents).